Trial intelligence / Profile preview

Adjuvant capecitabine plus oxaliplatin versus observation after neoadjuvant chemoradiation and clear-margin resection in locally advanced rectal cancer

ISRCTN59865116Phase 3Completed

Sponsor
University College London
Start
Nov 2004
Modality
Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules, DNA Intercalators/Alkylators → Nucleic Acid-Directed Small Molecules → Small Molecules
01

Overview

Phase 3, randomised, open-label trial of capecitabine and oxaliplatin in rectal cancer (2 arms), sponsored by University College London. Primary endpoint: Three-year disease-free survival. Started Nov 2004; status: completed.

02

Drugs

capecitabineoxaliplatin
03

Conditions

rectal cancer

Beyond the preview

Go deeper on ISRCTN59865116.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on ISRCTN59865116.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call